Inhalable drugs for systemic therapy.

Although oral and injectable drug formulations still dominate the market, interest in pulmonary delivery has been rising steadily. Given patients' desire for an alternative to injections, and recent advances in aerosol science and pulmonary medicine, the potential for improved disease management outcomes by using aerosols for systemic drug delivery should lead the way for a shift to inhalables.

[1]  M. Rawlins,et al.  Inhaled insulin , 2006, The Lancet.

[2]  J. Patton.  Inhalation delivery of therapeutic peptides and proteins. , 1999, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[3]  Pramod K. Gupta,et al.  Inhalation Delivery of Therapeutic Peptides and Proteins , 1997 .

[4]  A. Hickey,et al.  Generation and characterization of aerosols for drug delivery to the lungs , 1996 .

[5]  J. Patton,et al.  Mechanisms of macromolecule absorption by the lungs , 1996 .

[6]  B. Costa,et al.  [Diabetes and pharmacoeconomics. Efficiency of insulin injection methods available in Spain]. , 1995, Atencion primaria.

[7]  D. Wall.  Pulmonary Absorption of Peptides and Proteins , 1995 .

[8]  R. Niven,et al.  Delivery of biotherapeutics by inhalation aerosol. , 1995, Critical reviews in therapeutic drug carrier systems.

[9]  P. Gupta,et al.  Pulmonary delivery of therapeutic peptides and proteins , 1994 .

[10]  J. Patton,et al.  Bioavailability of pulmonary delivered peptides and proteins: α-interferon, calcitonins and parathyroid hormones , 1994 .

[11]  T. O'riordan,et al.  Aerosol deposition in mechanically ventilated patients. Optimizing nebulizer delivery. , 1994, American journal of respiratory and critical care medicine.

[12]  J. Patton,et al.  Drug delivery via the respiratory tract. , 1994, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[13]  R. Martin,et al.  The effects of inhaled interferon gamma in normal human airways. , 1993, The American review of respiratory disease.

[14]  J. Patton,et al.  (D) Routes of delivery: Case studies , 1992 .

[15]  R. Crystal,et al.  Anti-Neutrophil-Elastase Defenses of the Lower Respiratory Tract in α1-Antitrypsin Deficiency Directly Augmented with an Aerosol of α1-Antitrypsin , 1989 .

[16]  R. Crystal,et al.  Anti-neutrophil-elastase defenses of the lower respiratory tract in alpha 1-antitrypsin deficiency directly augmented with an aerosol of alpha 1-antitrypsin. , 1989, Annals of internal medicine.

[17]  A. Daugherty,et al.  Absorption of human growth hormone from the rat lung. , 1989, Biotechnology therapeutics.

[18]  P. Byron.  Prediction of drug residence times in regions of the human respiratory tract following aerosol inhalation. , 1986, Journal of pharmaceutical sciences.

[19]  American Conference Of Governmental Industrial Hygienists 1998 Ventilation A O , 2019 .